• Publications
  • Influence
Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance
This study aimed to evaluate endogenous metabolic markers of hepatic cytochrome P450 (CYP)3A activity in healthy subjects using a metabolomics approach. Twenty‐four subjects received the followingExpand
  • 78
  • 7
Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects
Pharmacokinetic and pharmacodynamic profiles of lorazepam and valproate were analyzed according to uridine 5′‐diphosphate‐glucuronosyltransferase (UGT)2B7 genotype in 14 healthy subjects withExpand
  • 81
  • 4
  • PDF
Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P‐Glycoprotein But Does Not Alter Its Antithrombotic Activity
Decreased oral clopidogrel absorption caused by induction of intestinal permeability glycoprotein (P‐gp) expression after aspirin administration was observed in rats. This study evaluated the effectExpand
  • 21
  • 4
  • PDF
Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects
  • S. Lee, B-H Kim, +5 authors K-S Yu
  • Medicine
  • Journal of clinical pharmacy and therapeutics
  • 1 December 2012
What is known and Objective:  Dexmedetomidine is a selective alpha2‐adrenoreceptor agonist used for sedation in critically ill patients. The current study aimed to evaluate the pharmacokineticsExpand
  • 38
  • 2
Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans
We hypothesized that the pharmacodynamic (PD) characteristics of metformin would change with inhibition of the multidrug and toxin extrusion (MATE) transporter, which mediates renal elimination ofExpand
  • 21
  • 1
Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers.
  • S. Yi, J. Kim, +9 authors K-S Yu
  • Medicine
  • International journal of clinical pharmacology…
  • 1 May 2011
UNLABELLED Fimasartan (BR-A-657) is an angiotensin II receptor antagonist, recently approved as an antihypertensive agent. OBJECTIVE This study aimed to investigate whether administration ofExpand
  • 18
  • 1
Pharmacodynamic comparison of two formulations of Acarbose 100‐mg tablets
What is known and Objective:  Acarbose, an α‐glycosidase inhibitor, is used to treat diabetic patients. Pharmacokinetic evaluation of acarbose is difficult because <2% is absorbed systemically. TheExpand
  • 9
  • 1
  • PDF
A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers
  • S. Yi, H. Lee, +5 authors K-S Yu
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 1 August 2017
YH4808, a K+‐competitive acid blocker, is under clinical development for the treatment of acid‐related disorders, such as gastroesophageal reflux disease.
  • 8
  • 1
  • PDF
Investigation of bioequivalence of a new fixed‐dose combination of acarbose and metformin with the corresponding loose combination as well as the drug–drug interaction potential between both drugs in
  • S. Kim, I. Jang, +10 authors Y. Wang
  • Medicine
  • Journal of clinical pharmacy and therapeutics
  • 1 August 2014
Both metformin and acarbose are recommended monotherapy and add‐on therapy in type 2 diabetes mellitus (T2DM). A fixed‐dose combination (FDC) of acarbose and metformin has been developed to reduceExpand
  • 4
  • 1
Modeling of Brain D2 Receptor Occupancy‐Plasma Concentration Relationships with a Novel Antipsychotic, YKP1358, Using Serial PET Scans in Healthy Volunteers
  • K. Lim, J. Kwon, +10 authors K-S Yu
  • Medicine
  • Clinical pharmacology and therapeutics
  • 1 February 2007
YKP1358 is a novel serotonin (5‐HT2A) and dopamine (D2) antagonist that, in preclinical studies, fits the general profile of an atypical antipsychotic. We conducted a D2 receptor occupancy study withExpand
  • 28
  • PDF
...
1
2
...